Evidence map›Paper›PMID 37721209›Full record

ArticleFuture microbiology2023

Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives.

Alessandro F Valdez, Daniel Zamith-Miranda, Leonardo Nimrichter, Joshua D Nosanchuk

Abstract read
In one paragraph

Article in Future microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alessandro F ValdezUniversidade Federal do Rio de Janeiro, Instituto de Microbiologia Paulo de Góes, Departamento de Microbiologia Geral, Rio de Janeiro - RJ, 21941-902, Brazil.ORCID 0000-0002-9285-3670
Daniel Zamith-MirandaDepartments of Medicine (Division of Infectious Diseases) & Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.ORCID 0000-0001-7532-2432
Leonardo NimrichterUniversidade Federal do Rio de Janeiro, Instituto de Microbiologia Paulo de Góes, Departamento de Microbiologia Geral, Rio de Janeiro - RJ, 21941-902, Brazil.ORCID 0000-0001-9281-6856
Joshua D NosanchukDepartments of Medicine (Division of Infectious Diseases) & Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.ORCID 0000-0001-9905-5754

Funding

Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosisR41AI165204 · NIAID · ZYLO THERAPEUTICS, INC. · PI DRAGANSKI, ANDREW R, NOSANCHUK, JOSHUA D · 2022 to 2023
$600k
Antibody differentially alters Histoplasma extracellular vesiclesR21AI124797 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI NOSANCHUK, JOSHUA D · 2016 to 2017
$538k
NIAID NIH HHS R21 AI124797NIAID NIH HHS R41 AI165204NIH HHS AI165204, R21 AI124797
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Candidadermatophytosisfungal infectionmicroparticlesnanoparticlesnitric oxideonychomycosistrichophyton

Identifiers

PMID37721209
PMCPMC10718170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.